News

Adipose-Derived Stem Cells Ameliorates Ischemia-Reperfusion Injury in a Rat Skin Free Flap Model

Francisco Miguel Sánchez Margallo, Scientific Director of CCMIJU and Javier García Casado, Scientific Director of NANBIOSIS U14, Cell Therapy Unit, are co-authors of the publication “Adipose-Derived Stem Cells Ameliorates Ischemia-Reperfusion Injury in a Rat Skin Free Flap Model”

The study was performed with the participation of the following NANBIOSIS Units: U21-Experimental operating rooms, U22-Animal housing, and U14-Cell Therapy

Article of reference: DOI: 10.1055/s-0038-1648246

Ballestín A, Casado JG, Abellán E, Vela FJ, Álvarez V, Usón A, Blázquez R, Sánchez-Margallo FM, J Reconstr Microsurg. 2018 May 3. [Epub ahead of print]

• Read More

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers.

The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of the Basque Country, led by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, which participates, through the CIBER BBN and the ICTS Nanbiosis, in the Drive Project focused on pancreatic cell transplantation and the development of biomaterials and new surgical devices that improve the transplantation and survival of insulin-producing pancreatic islets for the treatment of diabetes.

Dr. Pedraz explained for EIBT.eus Radio euskadi the aim of the DRIVE project: the transplantation of the cells of the pancreas, which consists of isolating the insulin-producing cells from a donor’s pancreas and implanting them in the patient with daibetes type I, not directly, but introduced into an artificial bio-pancreas by minimal invasive surgery . “Nowadays– explains Dr. Pedraz- obtaining pancreatic cells from stem cells or IPS cells is a not yet controlled process but it is an alternative source of insulin-producing cells. In the DRIVE project the most priority objective is to take the donor cells and introduce them into a device that will allow the patient to produce and release insulin in a more physiological way. In a second phase, it is intended to use differentiated insulin producing cells from the patient’s own cells, thus alleviating the shortage of donors”.

• Read More

Effect of Surface Chemistry and Associated Protein Corona on the Long-Term Biodegradation of Iron Oxide Nanoparticles In Vivo

The results of the research carried out by Scientists of U12. Nanostructured liquid characterization unit, and CIBER-BNN, have been published in an article by ACS Applied Materials & Interfaces:

DOI: 10.1021/acsami.7b18648

• Read More

Relevant research results for assisted reproduction.

Javier García Casado, Scientific Director of NANBIOSIS Unit 14: Cell therapy toguether with other Scientists of NANBIOSIS and CCMIJU have issued the first report describing the beneficial effect of human EV-endMSCs on embryo development, which has been recently published by PloS One: “Murine embryos exposed to human endometrial MSCs-derived extracellular vesicles exhibit higher VEGF/PDGF AA release, increased blastomere count and hatching rates“. The results could be relevant for assisted reproduction:

“Endometrial Mesenchymal Stromal Cells (endMSCs) are multipotent cells with immunomodulatory and pro-regenerative activity which is mainly mediated by a paracrine effect. The exosomes released by MSCs have become a promising therapeutic tool for the treatment of immune-mediated diseases. More specifically, extracellular vesicles derived from endMSCs (EV-endMSCs) have demonstrated a cardioprotective effect through the release of anti-apoptotic and pro-angiogenic factors. Here we hypothesize that EV-endMSCs may be used as a co-adjuvant to improve in vitro fertilization outcomes and embryo quality. Firstly, endMSCs and EV-endMSCs were isolated and phenotypically characterized for in vitro assays. Then, in vitro studies were performed on murine embryos co-cultured with EV-endMSCs at different concentrations. Our results firstly demonstrated a significant increase on the total blastomere count of expanded murine blastocysts. Moreover, EV-endMSCs triggered the release of pro-angiogenic molecules from embryos demonstrating an EV-endMSCs concentration-dependent increase of VEGF and PDGF-AA. The release of VEGF and PDGF-AA by the embryos may indicate that the beneficial effect of EV-endMSCs could be mediating not only an increase in the blastocyst’s total cell number, but also may promote endometrial angiogenesis, vascularization, differentiation and tissue remodeling”.

Soluble factors were analyzed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Maintenance of animals was performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). In vivo embryo recovery and culture was performed by the ICTS Nanbiosis (Unit 23. Assisted Reproduction at CCMIJU)

Article of reference:

Blázquez R, Sánchez-Margallo FM, Álvarez V, Matilla E, Hernández N, Marinaro F, Gómez-Serrano M, Jorge I, Casado JG, Macías-García B. “Murine embryos exposed to human endometrial MSCs-derived extracellular vesicles exhibit higher VEGF/PDGF AA release, increased blastomere count and hatching rates”. PLoS One (2018-04; vol. 13(4))

DOI: 10.1371/journal.pone.0196080

• Read More

20th European Conference on Integrated Optics

Prof Laura M. Lechuga, Scientific Director of NANBIOSIS U4 – Biodeposition and Biodetection Unit – is part of the Organising Committee of the 2018 European Conference on Integrated Optics that will celebrate its 20th anniversary in Valencia from the 30th May to the 1st June 2018. In the 2017 edition, which took place in Eindhoven, the conference featured more than two hundred attendees.

The conference focuses on leading edge research on integrated optics, optoelectronics and nano-photonics and gathers experts from academia and industry to show their latest technical results, and showcase their products and services.

The application scope is broad and it ranges from tele/datacom communications, optical interconnects, and (bio) optical sensing applications to more disruptive areas as quantum computing and mid-IR photonics.

• Read More

NANBIOSIS participation at VII Conference of Young Researchers of I3A

The I3A organizes the VII Conference of Young Researchers to be held on June 2, 2018. As in past editions, the Confernce will be addressed to all those who are doing the doctoral thesis whose director or co-director is a member of I3A.

Scientists of NANBIOSIS Unit 13 Tissue & Scaffold Characterization Unit will participate with the following poster:

Personalized simulation of intraestromal ring insertion surgery (ICRS). Validation with clinical data. Julio Flecha, Miguel Ángel Ariza-Gracia, Jesús Zurita, Begoña Calvo
Simulation of cell populations in Organ-On-Chip devices: of the models classics to data driven simulations. Jacobo Ayensa-Jiménez, Marina Pérez Aliacar, Teodora Randelovic, Sara Oliván, Iñaki Ochoa, Mohamed Hamdy Doweidar, Manuel Doblaré.

• Read More

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with diabetes and relatives who want to participate. “One of the objectives of this meeting is to better understand the expectations of people with diabetes and their doubts about the treatment of that disease. By giving us their opinion, they will help us to adapt the DRIVE project to their needs“, explained the organization.
The event is organized by the NanoBioCel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, directed by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, who participates in the DRIVE project through the CIBER BBN and the ICTS Nanbiosis, the only Spanish group in the project .
Admission is free and can be obtained at: https://www.ticketea.com/entradas-conferencia-drive-patient-panel/

• Read More

FORUM ON NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING

ICTS Nanbiosis, together with Nanomed Spain has organized a forum with companies on NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING that will take place next June 21 in Barcelona (Barcelona School of Management, Universitat Pompeu Fabra – C / Balmes, 132-134)

The forum will be presented through 2 sessions:
1- Short interventions of the latest advances and developments in the research lines developed by the groups and NANBIOSIS Units and description of the needs and demands of the industry in that area.
2- Bilateral meetings of about 15 minute company-group / NANBIOSIS Unit to identify possible collaborations.

The event will include the participation of the CDTI that will present the CDTI Financing Instruments for the use of Singular Scientific Technical Facilities and public-private collaboration

Registration is free and will be by order of registration until the capacity is exhausted.

Program and registration

• Read More

Prof. A. Villaverde interviewed by CIBER-BBN Bulletin

Prof. Antoni Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP), in an interview for the CIBER-BBN Bulletin, speaks about his research group, coordinanting NANBIOSIS u1 and the benefits of belonging to a research structure like CIBER.

“The PPP – explains Prof. Villaverde – was generated within the group, but is currently a platform that has been gaining its own entity and structure, and has received the ISO certification granted by AENOR. Neus Ferrer-Miralles is the Scientific Director and Paolo Saccardo the technical coordinator. The objective of the activity developed by the PPP is based on supporting CIBER groups in the production and purification of recombinant proteins within the field of nanomedicine. The fact that this service has emerged within a powerful research group allows the accumulated knowledge and experience to directly revert to the needs in this field within the area of nanomedicine in our country. Therefore, with the aim of reaching society, in addition to the CIBER, we also provide service to public and private entities dedicated to research and pharmaceutical companies”.

According to Toni Villaverde “The incorporation of the group to the CIBER-BBN has represented a clear and deap positive impact on our activities, at a collaborative level, which has greatly enriched our scientific and methodological capabilities and which has allowed a multidisciplinary scientific activity, which otherwise It would not have been possible. Since the beginning of the CIBER, we have carried out punctual collaboration activities with various groups of CIBER, and we have generated more stable collaborative structures that allow scientific developments in the medium-long term. Among the latter, it is necessary to highlight the collaboration with the group of Dr. Mangues and Dras. Isolda Casanova and Virtudes Céspedes,- coordinating NANBIOSIS U18.Nanotoxicology Unit, Profs. Veciana y Ventosa, coordinatinatin NANBIOSIS U6. Biomaterial Processing and Nanostructuring Unit, as well as of the group coordinated by Prof. Schwartz and Dr. Abasolo” –NANBIOSIS U20. In Vivo Experimental Platform-.

In this interview, Dr. Villaverde reviews the main research lines and projects that the research group at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona, coordinator of the NANBIOSIS U1.PPP, is currently developing (nanostructured protein materials as therapeutic anti-inflammatory agents, nano and protein microstructures for drug delivery in targeted therapies and new drugs for rare diseases, nanoconjugates based on self-assembling proteins for targeted cancer therapy, self-assembling and nanostructured protein drugs, produced in recombinant form and based on very potent toxins, for targeted molecular therapy of cancer… and much more…) .

For further information: click here

• Read More

Nosological images of response to therapy based on metabolomic information by magnetic resonance

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I. is givin a talk about “Nosological images of response to therapy based on metabolomic information by magnetic resonance: a step beyond the standard image” next June 6, on Barcelona.

According to Dr. Candiota, “The reliable characterization of the treatment response in glioblastoma (GB) is a key factor in improving the survival and prognosis of patients. Image (MRI) and spectroscopic image (MRSI) by magnetic resonance respectively provide morphological and metabolotic profiles of GB, but in general they are not as robust to produce surrogate biomarkers in response to short-term therapy. One of our objectives is to try to provide clinicians with a reliable way to follow the response to therapy in a more adjusted temporal window for changes or adaptations of the therapy, and in a more early way than the one currently performed using MRI. This part of the course will emphasize the potentiality of the systems of patterrn recognition / machine learning to produce ‘nosological images’ to recognize in a robust way the response to temozolamide (TMZ) therapy in preclinical GB (glioblastoma GL261 murine model in the immunocompetent strain C57 / BL / 6), based on the information of the magnetic resonance spectroscopic images. Despite being developed on a preclinical model of pathology, these techniques have a clear translational potential and could in the future improve the management of the different aspects of the treatment of patients”.

The talk will take place in the Conference: Nanotechnology applied to medicine as a learning resource for healthcare professionals, organized by Union Consorci Formació in Barcelona (Parc Sanitari Pere Virgili, Edifici Montseny planta -1).

The objective of the event is to summarize the most significant advances that have been made in this field, both at the level of development of nanomaterials, as well as in the most relevant applications of the different nano-pharmaceuticals that are on the market, to end up highlighting the future challenges to which faces nanomedicine to increase the efficiency and specificity of nanomedication.

Programa e inscripciones: Inscription is free but the number of places is limited.

• Read More

You are here : Home / News (Page 63)